- Iomab-B and
Actimab-A are the only targeted radiotherapies in for acute myeloid
leukemia addressing different parts of the patient journey
- Improved
survival demonstrated with both Iomab-B and Actimab-A in patients
with high-risk acute myeloid leukemia including those with a TP53
mutation and prior venetoclax treatment
- Novel
linker technology supports Actinium's Antibody Radiation Conjugate
pipeline expansion in solid tumor indications
NEW
YORK, May 13, 2024 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of Antibody Radiation
Conjugates (ARCs) and other targeted radiotherapies, today
announced that five abstracts have been accepted for presentation
at the 2024 Society of Nuclear Medicine & Molecular Imaging
(SNMMI) Annual Meeting being held June
8 – 11, 2024, in Toronto,
Canada. The abstracts will feature results from the Phase 3
SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodine-131
payload, intended for conditioning to prepare patients for a
potentially curative bone marrow transplant (BMT) and results from
a Phase 1b trial of Actimab-A, a CD33
targeting ARC with the Actinium-225 payload, in combination with
the chemotherapy regimen CLAG-M. Iomab-B and Actimab-A are
the only targeted radiotherapies in development for patients with
relapsed/refractory acute myeloid leukemia (r/r AML), a blood
cancer that is highly sensitive to radiation. In addition, an
abstract detailing proprietary linker technology applicable for
solid tumor targeting ARCs developed by Actinium will be presented
for the first time.
Sandesh Seth, Actinium's Chairman
and CEO, said, "Our presence at this year's SNMMI showcases the
breadth of Actinium's capabilities and leadership in the
development of Antibody Radiation Conjugates. We look forward to
highlighting the potential for targeted radiotherapy in blood
cancers to the nuclear medicine community, which represents a
significant expansion opportunity for the field. The data from
Iomab-B and Actimab-A that will be presented at SNMMI demonstrate
the potential of targeted radiation to treat patients with
high-risk, difficult-to-treat r/r AML, including the ability
overcome mutations such as TP53 and those who have had extensive
prior therapies."
Actinium's SNMMI presentations are detailed below:
Safety and Dosimetric Analysis of Lintuzumab-Ac225 in
Combination with Intensive CLAG-M Chemotherapy in Patients with
Relapsed/Refractory AML
Exploratory Analysis of Bone Marrow Dosimetry from the
Randomized Phase 3 SIERRA Trial of Iomab-B (131I-apamistamab) Prior
to HCT in Relapsed/Refractory Acute Myeloid Leukemia
Survival Outcomes and Dosimetric Analysis of Iomab-B
(131I-apamistamab) Followed by Allogeneic Hematopoietic Cell
Transplant for Patients with TP53 Mutated Relapsed/Refractory
AML
Mathematical Modeling of Exposure Measurements Following
High-Dose Targeted Therapy Using 131I-apamistamab: Analysis From
the Large Multicenter Phase III SIERRA Trial
Evaluation of novel DOTA-based linkers for improved targeted
radiotherapy delivery to solid tumors
About the SNMMI Annual Meeting
The SNMMI Annual Meeting is recognized as the premier
educational, scientific, research, and networking event in nuclear
medicine and molecular imaging. The four-day event, taking place
each June, provides physicians, technologists, pharmacists,
laboratory professionals, and scientists with an in-depth view of
the latest research and development in the field as well as
providing insights into practical applications for the clinic.
About Actinium Pharmaceuticals, Inc.
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA & MAA
(EU)), an induction and conditioning agent prior to bone marrow
transplant, and Actimab-A (National Cancer Institute CRADA pivotal
development path), a therapeutic agent, have demonstrated potential
to extend survival outcomes for people with relapsed and refractory
acute myeloid leukemia. Actinium plans to advance Iomab-B for other
blood cancers and next generation conditioning candidate Iomab-ACT
to improve cell and gene therapy outcomes. Actinium holds more than
230 patents and patent applications including several patents
related to the manufacture of the isotope Ac-225 in a
cyclotron.
For more information, please
visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Investors:
investorrelations@actiniumpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-announces-multiple-abstracts-highlighting-its-antibody-radiation-conjugates-iomab-b-and-actimab-a-and-novel-linker-technology-for-solid-tumors-accepted-for-presentation-at-the-2024-society-of-nuclear-medicine--molecular--302143193.html
SOURCE Actinium Pharmaceuticals, Inc.